简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2023-07-27 10:26 AmbioPharm, a Global Peptide CDMO
2023-07-26 11:32 BaroPace Receives Approval for First-in-Human Clinical Trial
2023-07-25 21:44 Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
2023-07-25 13:46 Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement
2023-07-25 13:28 Orthogon Therapeutics Celebrates Major Technical Milestone and Secures Additional $6M Toward a Pioneering Drug for BK Virus
2023-07-21 06:44 Kenvue Initiates Quarterly Cash Dividend
2023-07-20 16:43 New Data Shows Advantages of Rapid Medical’s COMANECI™ Embolization Assist Device
2023-07-19 20:47 Exscientia Initiates Prospective Observational Study in Ovarian Cancer
2023-07-17 17:17 TauRx’s Hydromethylthionine Mesylate (HMTM) Demonstrates Significant Reduction in Neurodegeneration in Alzheimer’s Disease (AD)
2023-07-14 16:43 Pacific Prime’s Study Reveals Global Premium Hikes Impacting International Health Insurance Plans
2023-07-13 13:54 JEOL: Release of Scanning Electron Microscopes JSM-IT710HR/JSM-IT210
2023-07-12 21:27 Eli Lilly Selects ABEC for World’s Largest Single-Use Biopharmaceutical Manufacturing Facility
2023-07-12 10:08 World’s Largest Independent Health Agency Opens in Asia-Pacific
2023-07-11 17:21 First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
2023-07-11 08:48 Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing
2023-07-11 08:40 Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program
2023-07-06 15:59 Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
2023-07-06 10:25 First Distribution Agreement Executed with Sonic Healthcare
2023-07-05 08:34 P&G Grooming Invites Dermatologist Community to Go ‘Skin Deep Into Grooming’ at the 25th World Congress of Dermatology
2023-07-04 18:36 Galderma @ WCD 2023: Late-Breaking Phase III Results for Nemolizumab Monotherapy in Prurigo Nodularis Show a Significant Proportion of Itch-Free Patients by Week 4

Business Wire Weibo

Press Releases

Latest Releases